The first proof that a targeted nanoparticle — used as an experimental therapeutic and injected directly into a patient’s bloodstream — can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi) has been published in the journal Nature by a Caltech-led team of researchers and clinicians.

More info: Caltech News